Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

NCT01693276 is registered in ClinicalTrials.gov with Olugbenga Olowokure as lead sponsor.

NCT NCT01693276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01693276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
Lead sponsor
Olugbenga Olowokure
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2012
Completion date
June 30, 2014
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer